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Introduction: Surgical resections for gastric carcinoma are a commonly 
encountered histopathologic specimen. Despite this, gastric carcinoma in South 
Africa and particularly within the Western Cape Province has not been well 
documented. 
Aims: To interrogate the WNT signalling pathway using selected protein 
expression by immunohistochemistry and correlating these with tumour subtypes. 
To assess Her2/neu expression and correlate this with morphologic subtypes 
Objectives: To determine aberrations in the expression of β-catenin, E-cadherin 
(extracellular and cytoplasmic domains) and DVL1 in gastric carcinoma 
subtypes. Additionally, to determine Her2/neu overexpression by 
immunohistochemistry and correlate this with morphologic subtype. 
Materials and methods: 97 gastric adenocarcinoma resection cases were 
retrieved and stained with antibodies against β-catenin, DVL1, E-cadherin 
(extracellular domain), E-cadherin (cytoplasmic domain) and Her2/neu. Results 
were considered statistically significant if P < 0.05. 
Results: All 97 cases were confirmed as gastric adenocarcinomas, with 39 (40%) 
intestinal type, 51 (53%) diffuse type and 7 (7%) mixed type tumours identified 
respectively. Patient ages ranged from 18 to 84 years. Her2/neu was 
overexpressed in 12 (12%) cases, with 9 of these cases showing intestinal-type 
morphology (P = 0.0174). Abnormal β-catenin localisation occurred in 14 (14%) 
cases. Aberrant E-cadherin (extracellular domain) localisation or absent staining 
was seen in 36 (37%) cases, with a significant proportion demonstrating diffuse 
type morphology (P <0.001). Abnormal E-cadherin (cytoplasmic domain) 
localisation or absent staining was seen in 7 (7%) cases, with a significant 6 of 
these 7 cases showing diffuse-type morphology (P = 0.0231). Eleven (11%) cases 
were seen in patients younger than 40 years, with 9 of these cases showing 
intestinal morphology and a significant 7 of the 11 cases showing aberrant  E-




Conclusion: Gastric adenocarcinomas show derangements in the WNT 
signalling pathway. Distinct immuno-morphologic correlations are apparent in 
tumours demonstrating Her2/neu overexpression or abnormal E-cadherin 
localisation. Tumours occurring in younger individuals show intestinal 
morphology, poor differentiation and E-cadherin abnormalities.  
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1 Introduction and Literature review 
 
1.1 Introduction 
Gastric carcinoma is a malignant epithelial neoplasm that is not uncommonly 
encountered in histopathology resection specimens, with adenocarcinoma 
representing 80-90% of all types of gastric carcinoma. [1] These neoplasms 
demonstrate distinct differences in their immunohistochemical profile and 
prognosis, dependent in part, on their morphology, demographic distribution and 
underlying genetic aberrations. 
The occurrence of gastric carcinoma in South Africa and in particular within the 
Western Cape Province has not been well documented. The following literature 
review takes into account the current worldwide knowledge base regarding the 
specific demographics, aetiopathogenesis, morphology, immunohistochemical 
staining profile and molecular pathways of gastric adenocarcinoma and compares 
these features to cases found within the Western Cape. 
 
1.2 Historical perspective 
During the late 1970’s and early 1980’s, gastric adenocarcinoma was considered 
the commonest primary malignant epithelial neoplasm, with up to 650 000 new 
cases reported per year. [2] In 2002, this figure increased to 930 000 new cases of 
gastric carcinoma per year. [3] This is however no longer the case in the current 
socioeconomic climate, with lung cancer now the leading malignant cancer 
worldwide. There has been a steady decline in the frequency of gastric 
adenocarcinoma, in part due to the understanding of its association (and 
subsequent antibiotic and medical treatment) with Helicobacter pylori (H.pylori) 





1.3.1 Incidence and geographic distribution 
Gastric carcinoma remains a leading cause of death worldwide, being the fourth 
most common cause of cancer related death. [5] The incidence varies widely, 
with defined high risk and low risk areas having been identified. High risk areas 
include Japan, China, Chile and Portugal. Low risk areas include the United 
States of America and the United Kingdom. [6] South Africa is considered a low-
to-intermediate risk region. [3] In Asian countries, Japan has the highest 
incidence rates of gastric carcinoma, with up to 115 cancers per 100 000 
population per year. Portugal has the highest incidence amongst Western 
European countries, with 33 cancers / 100 000 population per year. 
Comparatively, South Africa has an incidence rate of 11.9 cancers per 100 000 
population per year. [7] The Lauren classification divides gastric adenocarcinoma 
into intestinal and diffuse subtypes, based on morphology. The intestinal subtype 
appears to predominate in high risk areas and arises from precursor lesions. 
However the diffuse type of gastric adenocarcinoma does not exhibit a 
geographic predominance and no definitive precursor lesion has been identified. 
In addition, patients in low risk areas develop proximal (cardia and fundal) 




Gastric carcinoma is predominantly a disease of middle aged to elderly 
individuals. Most patients present between the ages of 40 and 70 years, with a 
mean age at presentation of 52 years. Gastric carcinoma in patients younger than 
40 years (early-onset gastric carcinoma) is uncommon, accounting for less than 
5% of cases. [8, 9] These early-onset cases differ in their sex incidence (with 
either an equal male-to-female ratio or female predominance), morphology, 
(diffuse type rather than intestinal type), poor differentiation and generally have a 
poor prognosis. [8, 9, 105]  Matley et al, 1988 [8] showed that this also holds true 
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for cases seen within the Western Cape in South Africa. Additionally, some cases 
of early onset gastric carcinoma have been shown to harbour a germline mutation 
in the CDH1 gene, encoding for E-cadherin. [10]  
 
1.3.3 Gender 
Gastric carcinoma shows a strong male predominance, with an approximately 2:1 
male to female ratio. [102] The male prevalence of gastric carcinoma is greater in 
high incidence areas. Powell and McConkey, 1990 [11] showed a consistently 
higher male-to-female ratio in gastric carcinomas arising in the cardia compared 
to those arising in the distal stomach (antrum and pylorus). Gastric carcinoma 
occurring in patients younger than 40 years, show a 1:1 or 0.9:1 male-to-female 
ratio. [8, 9] 
 
1.3.4 Race and socio-economic status 
Worldwide, gastric adenocarcinomas are more common in Asians and Blacks 
than in Caucasians. [12] Within South Africa, many more Coloured individuals 
are affected by the disease, with 98 cancers / 100 000 population. [13] 
Additionally, worldwide and within Southern Africa, increased rates of gastric 







Gastric carcinoma is a multifactorial and multistep process that often involves a 
step-wise progression from normal gastric mucosa, though chronic gastritis, 
atrophic gastritis and intestinal metaplasia, dysplasia, carcinoma in-situ and 
ultimately to invasive carcinoma. 
Risk factors commonly implicated in the development of the disease can be 
subdivided into three broad categories. 
- Environmental factors 
The most important factor in the development of gastric carcinoma is infection by 
H.pylori. Diets rich in salts and nitrites and diets low in antioxidants have also 
been implicated in carcinogenesis through the formation of carcinogenic N-
nitroso compounds. Rare cases of Epstein-Barr virus (EBV) associated gastric 
carcinomas have been reported. [15] 
- Host factors 
The commonest host factors include chronic atrophic gastritis with intestinal 
metaplasia, partial gastrectomy with bile reflux and the presence of gastric 
adenomas with high grade dysplasia. Autoimmune gastritis and Menetrier’s 
disease are considered uncommon precursor lesions in gastric adenocarcinoma 
development. [16] 
- Genetic factors 
Germline mutations in the CDH1 gene (encoding E-cadherin), [10] a family 
history of gastric adenocarcinoma, the presence of Hereditary Non-polyposis 
Cancer Syndrome (HNPCC) [17] and Familial Adenomatous Polyposis (FAP) 





1.4.1 H.pylori in gastric carcinoma 
H.pylori plays an integral role in the development of gastric adenocarcinomas 
through a complex interaction between bacterial virulence factors, cytokines, free 
radicals and host immunity. [19] H.pylori is a Gram-negative curvilinear 
coccobacillus that resides within the gastric mucus of infected individuals. It 
produces a number of factors that disrupt the normal mucosal barriers of the 
stomach and act as promoters of carcinogenesis 
These include: 
- Production of urease  
Urease is a bacterial produced enzyme that results in the metabolism of urea to 
ammonia and carbon dioxide, thereby buffering gastric acid in the immediate 
vicinity of the organism. Ammonia gets further degraded to carcinogenic nitrate 
and nitrite intermediates via the nitrogen cycle  
- Cytotoxin associated gene A (Cag A )  
Cag A is a virulence factor associated with increased colonisation of mucus by 
organisms, increased epithelial damage, increased inflammatory response and 
increased carcinogenic potential. Cag A-positive strains of H.pylori are 
associated with an increased incidence of distal gastric carcinoma while being 
rare in gastric cardia carcinoma. [20] 
- Vacuolating gene A (Vac A)  
Vac A is an associated virulence factor which requires Cag A for normal 
functioning. The combination of Cag A and Vac A results in an intracytoplasmic 
passive transport system, with intracytoplasmic vacuole formation and increased 
urea transport to the surface epithelium. The end result is an increased urea load, 
with subsequent urease degradation within the gastric mucus and ultimately 




- Phospholipase production  
Phospholipase is a bacterial produced enzyme that causes destruction of the 
cytoplasmic membrane phospholipid bilayer of gastric epithelial cells. This 
decreases intrinsic host defences and causes seepage of host intracellular 
metabolites into the mucus, providing nutrients to the bacilli. 
- Protease production 
Similar to phospholipase, protease is a bacterial produced enzyme that causes 
destruction of glycolipid complexes within the gastric mucus. This causes 
alteration of normal gastric mucus structure, thus decreasing intrinsic host 
defences and rendering the gastric epithelial cells more prone to bacterial 
damage. 
 -     Upregulation of host immunity and hypochlorhidria 
H.pylori infection results in the production of the pro-inflammatory cytokines 
interleukin 1, interleukin 6, interleukin 8 and tumour necrosis factor alpha (TNF-
α) by mucosal epithelial cells, with subsequent recruitment and activation of 
neutrophils. Enhanced expression of interleukin 1 beta (IL-1β) is an inhibitor of 
gastric acid secretion, resulting in decreased gastric acid production and 
hypochlorhidria. Increased colonisation of gastric mucus by H.pylori organisms 
results in a pangastritis, development of atrophic gastritis and subsequent 
increased risk of gastric carcinoma. [21] Additionally, IL-1β further upregulates 
TNF-α, which is also an inhibitor of gastric acid production. [22] 
- Increased free radical production 
The active inflammation associated with H.pylori infection results in the 
production of free radicals and activation of nitric oxide. [23] Nitric oxide further 
combines with these oxygen-derived free radicals to form highly reactive oxygen 
species that directly damage gastric epithelial cells and cause mutations within 





- Decreased gastric anti-oxidant levels 
A diet rich in fresh fruits and vegetables, combined with increased intake of 
vitamin C and vitamin E, aid in scavenging oxygen-derived free radicals, thus 
preventing the formation of carcinogenic N-nitroso compounds. Studies have 
shown that, by mechanisms which are unclear, H.pylori infection results in 
decreased levels of vitamins C and E both within gastric epithelial cells and 
within the gastric mucus. [25, 26] 
-    Increased epithelial cell proliferation and increased risk of mutations 
H.pylori associated chronic gastritis represents an epithelial hyperproliferative 
state, with expansion of the proliferative zone within gastric pits. [27] The 
normally non-dividing Paneth cells and goblet cells (which occur in the setting of 
intestinal metaplasia) are also noted to show increased proliferative activity, 
implying a component of cell-cycle dysregulation and increased propensity to 
carcinogenic inducing mutations. [28] 
 
In addition to the above factors, H.pylori plays an integral role in activation of the 





1.4.2 The WNT signalling pathway 
The WNT’s represent a ubiquitous family of protein ligands that play a critical 
role in embryogenesis, cell migration, tissue homeostasis and neoplasia. The 
term, WNT, was first coined by Nusse et al [30] in 1991 to describe a 
combination of the homologous wingless (wg) gene discovered on the Drosphilia 
menalogaster fruitfly and the Int1 (Wnt1) murine mammary tumour oncogenic 
integration site gene. [31] Recessive mutations in wg are associated with failure 
of wing development in fruitflies, while Int1 aberrations cause mammary 
carcinoma in mice. 
 
1.4.2.1 Members of the WNT family 
There are currently 19 human WNT genes, as defined by their amino acid 
sequences. [32] These WNT genes are: WNT1, WNT2, WNT2B, WNT3, WNT3A, 
WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, 
WNT9B, WNT10A, WNT10B, WNT11 and WNT16. [33] 
 
WNT’s are glycoproteins with characteristic spacing of cysteine amino acid 
residues [34] that bind to receptors with cysteine-rich domains. These receptors 
include, amongst others, Frizzled (FZD), low density lipoprotein receptor related 
protein (LRP) and transmembrane tyrosine kinases. 
 
FZD receptors are G-protein coupled receptors. Ten FZD receptors are currently 
identified in humans. The N-terminal of FZD receptors represents the cysteine-
rich WNT binding domain. Secreted frizzled-related proteins (SRFP) are the 
secreted forms of FZD that bind WNT. Upon binding to WNT, they act as 
inhibitors of the pathway. 
 
LRP5/6 is a member of the low density lipoprotein receptor related protein (LRP) 
family and plays an integral role in WNT signalling through co-binding of WNT 




1.4.3 The canonical WNT signalling pathway 
Two closely linked and inter-related pathways exist in WNT signalling. The first 
pathway is a β-catenin dependent pathway, known as the canonical pathway. 
Two β-catenin pools are present within human cells. The membrane-bound pool, 
through its interaction with the E-cadherin cell adhesion molecule, aids in cell-
cell interaction by binding to the actin cytoskeleton. A second, WNT regulated β-
catenin pool is present within the cytoplasm.  
 
In the absence of WNT signalling, β-catenin is phosphorylated, resulting in its 
eventual proteosomal degradation via an E3 ubiquitin ligase process. [35] 
Glycogen synthase kinase 3β (GSK3β) and Casein kinase 1 α (CK1α) mediate the 
process of phosphorylation by interaction with Axin and Adenomatous polyposis 
coli (APC) proteins, ultimately forming an APC-Axin- GSK3β-CK1α  complex 
With WNT binding to FZD, via the LRP5/6 co-receptor, there is formation of a 
WNT-FZD-LRP5/6 trimer. Subsequently, FZD binds to Dishevelled (DVL) and 
there is phosphorylation of the cytosolic tail of LRP5/6. The phosphorylated 
LRP5/6 then binds to Axin and inactivates the APC-Axin-GSK3β-CK1α 
complex. β-catenin remains unphosphorylated and accumulates within the 
cellular cytoplasm. Nuclear translocation of β-catenin then occurs, whereupon it 
acts as a potent transcription co-regulator through its interaction with nuclear 
transcription factors. β-catenin associates with T cell factor/lymphoid enhancer 
factor (TCF/LEF) family transcription factors (TCF1, LEF1, TCF3 and TCF4) 
that subsequently activate downstream target genes. These target genes include, 






Figure 1: Schematic representation of the WNT signalling pathway  
 
In an attempt to prevent inappropriate WNT signalling, both intracellular and 
extracellular regulators and inhibitors of WNT signalling are present. 
Intracellular regulators include Sex determining region Y box 9 (SOX9). 
Extracellular inhibitors are multiple and include, amongst others, SRFP [37] and 
the Dickkopf [33] family of genes. 
 
The canonical WNT pathway plays a critical role in stem cell maintenance and 
tissue development in both foetal and adult tissues. [38] Aberrations in this 
canonical pathway by abnormal constitutive activation (through ligand over-
expression or down-regulation of intracellular or extracellular inhibitors), results 





1.4.4 The non-canonical WNT signalling pathways 
The non-canonical WNT signalling pathways regulate critical events during 
embryogenesis. The mechanisms that underlie the activation of the non-canonical 
pathway are poorly understood. 
The non-canonical pathways are multiple and are best defined as pathways that 
are WNT and FZD mediated, but independent of β-catenin transcriptional 
activity. [39] The three components that comprise this pathway are the: WNT-
polarity pathway, WNT-Ca²+ pathway and WNT-atypical protein kinase C 
pathway, mediated by WNT family members WNT4, WNT5A and WNT11. These 
pathways are involved in the development of planar cell polarity in Drosphilia, 
and neuronal and epithelial cell migration. 
The WNT polarity pathway ensures normal epithelial and neuronal cellular 
polarity, mediated by interactions with DVL and FZD. [40, 41] 
The WNT-Ca²+ pathway is mediated by WNT binding to FZD, resulting in G-
protein coupled receptor activation. Intracellular calcium is released with 
subsequent activation of Ca2+ dependent transcription factor nuclear factor 
associated with T cells (NFAT). [42] Additionally, there is paradoxical 
interaction with the canonical pathway, whereby the WNT-Ca²+ pathway serves 
as an inhibitor of β-catenin, preventing canonical signalling. 
The WNT-atypical protein kinase C pathway is a poorly understood regulatory 
mechanism of neuronal/neuroectodermal differentiation and ordered assembly. It 
involves a complex series of interactions between DVL and atypical protein 
kinase C (aPKC), whereby DVL directly regulates aPKC activity in hippocampal 
neurons. Downregulation of DVL reduces axon differentiation while DVL 





1.4.5 WNT signalling in human diseases and cancer 
WNT’s play an integral role in cellular movement, cellular polarity, cellular 
proliferation and cellular destruction in both adult and stem cells. [30] Mutations 
in WNT genes are associated with developmental abnormalities, while aberrations 
in WNT signalling pathways are associated with neoplasia and certain 
multisystemic diseases. (Table 1) 
Table 1: WNT genes associated with human disease (modified from Logan and 
Nusse, 2004) [44] 
Gene Human disease 
WNT5a Gastric carcinoma [79] 
APC Gastric carcinoma [57], Polyposis coli 
[51], colon cancer [52] 
WNT3 Tetra-amelia [45] 
LRP5 Bone density defects [46], Vascular 
defects in the eye (osteoporosis-
pseudoglioma syndrome; OPPG) [47], 
familial exudative vitreoretinopathy; 
(FEVR) [48] 
FZD4 FEVR [48, 49] 
Axin2 Tooth agenesis, 




Genetic alterations, constitutive activation and mutations of genes within both the 
canonical and non-canonical WNT signalling pathways are associated with 
human cancer development [Table 2]. [53] Colorectal adenocarcinoma is a well-
studied and frequently encountered histopathologic specimen, demonstrating 
mutually exclusive mutations in APC and β-catenin. APC mutations are 
encountered in colorectal adenocarcinomas occurring in the setting of familial 
adenomatous polyposis (FAP), as well as approximately 80% of sporadic 
colorectal adenocarcinomas. [54] Up to 10% of sporadic colorectal 
adenocarcinomas demonstrate a mutation in β-catenin. [55] Additionally, β-
catenin mutations are noted in approximately 40% of HNPCC-associated 
colorectal adenocarcinomas. [56] 
β-catenin mutations are frequently associated with invasive and non-invasive 
human neoplasms. These include pancreatic solid pseudopapillary tumours, [65] 
hepatocellular carcinomas, medulloblastomas [54], ovarian endometrioid 
borderline tumours and ovarian invasive endometrioid adenocarcinomas [66] and 
pulmonary blastoma. [67] 
In gastric adenocarcinoma, β-catenin mutations (particularly mutations within 
exon 3 of the β-catenin gene) occur in 25 - 60 % of cases. [98, 99] These 
mutation positive cases can be detected immunohistochemically by the presence 
of aberrant nuclear β-catenin staining. [68] A genotype-phenotype correlation is 
present, with a strong association noted between nuclear β-catenin accumulation 
and intestinal type morphology. [101] 
Linked to β-catenin in the canonical WNT pathway is E-cadherin. 
Downregulation of E-cadherin and loss of immunohistochemical membrane 






Table 2:  Genetic alterations in WNT signalling (modified from Polakis, 2012) 
[53] 
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Both the canonical and non-canonical WNT signalling pathways play a critical 
role in gastric adenocarcinoma. Studies have shown that β-catenin independent 
non-canonical signalling with increased expression of WNT5A is associated with 
aggressive behaviour in gastric adenocarcinoma, by stimulation of cell migration 
and enhancing the invasive capabilities of the tumour cells. [79] 
 
Additionally, β-catenin mutation (canonical pathway) is a frequent cause of 
inappropriate activation of the WNT pathway in gastric carcinoma. [68] In an 
attempt to prevent this inappropriate WNT signalling, both intracellular and 
extracellular inhibitors of WNT signalling are present. Secreted frizzled-related 
protein 1 (SRFP) serves as a critical extracellular inhibitor. Studies have linked 
epigenetic inactivation of SFRP genes to constitutive activation of WNT 




1.4.6 The role of E-cadherin in gastric carcinoma 
Epithelial-cadherin (E-cadherin) is a member of the cadherin superfamily, 
serving as the main epithelial intercellular adhesion molecule. It is encoded by 
CDH1, a gene present on the long arm of chromosome 16. The encoded protein is 
a calcium dependent cell-cell adhesion molecule. E-cadherin plays a critical role 
in the normal architecture of epithelial tissues and in cell differentiation through 
its interaction with the catenin group of molecules. [95] E-cadherin consists of 5 
repeats within the extracellular domain, a transmembrane domain and a 
phosphorylated intracellular domain. This intracellular domain links E-cadherin 
to the WNT signalling pathway via its binding of p120 and β-catenin. 
 
Closely aligned to tumour stromal invasion is the process of epithelial-
mesenchymal transition. In a normal state, E-cadherin acts as a tumour 
suppressor gene through maintenance of cell-cell adhesion and sequestration of 
β-catenin on the cell membrane. When E-cadherin expression is downregulated, 
the loss of E-cadherin results in release of β-catenin into the cytoplasm [94]. 
Subsequent translocation of β-catenin into the nucleus occurs and ultimately 
results in the upregulation of epithelial-mesenchymal related transcription factors. 
These transcription factors cause a change in phenotype from a cohesive 
epithelial cell to a motile and discohesive mesenchymal cell that has increased 
stromal invasive abilities. 
Downregulation of E-cadherin can occur as a result of CDH1 gene mutations 
(both germline and somatic), CpG island promoter hypermethylation or 
epigenetic silencing (through the actions of Snail, Slug and Twist). [83] 
This downregulation of E-cadherin expression occurs in the malignant 
progression of carcinomas and is seen in lobular breast carcinomas and 





Hereditary diffuse gastric carcinoma is an autosomal dominant condition caused 
by a germline mutation in CDH1. It accounts for less than 1% of all gastric 
malignancies and is characterised by gastric carcinoma occurring in patients 
younger than 40 years, loss of E-cadherin expression, diffuse type morphology 
and early death. [104] 
Loss of E-cadherin expression (which can be demonstrated by 
immunohistochemical staining) is associated with poor tumour differentiation, 
increased tumour grade, increased metastasis and poorer prognosis. [81, 82, 83, 
90]  
 
1.4.7 Dishevelled in gastric carcinoma 
Dishevelled (DVL) is a cytoplasmic phosphoprotein that acts downstream of 
FZD receptors in the WNT signalling pathway. Three human DVL genes have 
been identified, namely DVL1, DVL2 and DVL3. [96] 
DVL1 is a candidate gene in the process of neuroblastomatous development and 
aberations in DVL1 may play a role in the development and phenotypic 
manifestations of Charcot-Marie-Tooth disease. 
Though the role of DVL in the WNT signalling pathway is well established, [96, 
97] its direct role in gastric carcinoma pathogenesis is not well elucidated. 
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1.4.8 Human epidermal growth factor receptor gene 2 (Her2/neu) 
and targeted therapy in gastric carcinoma 
Her2/neu is an oncogene on chromosome 17q12–q21, encoding a 185-kDa 
transmembrane tyrosine kinase receptor (p185), which is a member of the 
epidermal growth factor receptor family. 
Approximately 20% of gastric adenocarcinomas overexpress Her2/neu. 
Overexpression of Her2/neu can be assessed by both immunohistochemistry and 
fluorescent in-situ hybridisation (FISH) techniques, with a strong concordance 
between the two. [87] 
Molecular therapy targeting Her2/neu (anti Her2/neu monoclonal antibody 
Trastuzumab/Herceptin) is currently approved for the treatment of advanced 
gastric adenocarcinoma and metastatic gastric adenocarcinoma, if the carcinoma 
demonstrates unequivocal evidence of Her2/neu overexpression (by 
immunohistochemistry) or amplification (by FISH). 
The multinational ToGA trial validated the Her2/neu testing criteria for the 
determination of overexpression and amplification, [84] with 
immunohistochemically determined overexpression equating to a score of 3+ and 
FISH determined amplification by a Her2:CEN17 ratio of greater than two (Her2 
: CEN17  >2.0). 
Large studies have evaluated the significance of Her2/neu expression in gastric 
carcinoma and its effect on patient survival, with conflicting data emerging. Marx 
et al, 2009 [85] and Kunz et al, 2011 [86] showed no association between these 
parameters. However, studies by Kim et al, 2007 [87], Yan et al, 2010 [88] and 
Choong Kim et al, 2011 [89] showed that Her2/neu overexpression was 
associated with decreased patient survival and an overall poorer prognosis. 
No correlation between Her2/neu overexpression/amplification and tumour stage 
has been established. However, a strong morphologic correlation with Her2/neu 
overexpression/amplification is present. Using this parameter, intestinal type 
tumours showed a higher rate of Her2/neu positivity (32%) than diffuse type 




1.5 Clinical features 
1.5.1 Presenting features 
Gastric adenocarcinoma is a disease of insidious onset with variable clinical 
features and a frequent initial asymptomatic period. The initial presentation is 
often non-specific with vague upper gastrointestinal symptoms including 
anorexia, nausea, vomiting and dyspepsia. Patients with more advanced lesions 
complain of weight loss, an epigastric mass, dysphagia, haematemesis and 
melaena. A subcutaneous umbilical nodule (Sister Mary Joseph nodule) may be 
present and represents a periumbilical metastatic deposit. Additionally, there may 
be supraclavicular lymphadenopathy (Virchow Trossier node) due to lymph node 
metastasis. Distinctive bilateral ovarian gastric adenocarcinoma metastases can 
occur (Krukenburg tumour). 
1.5.2 Diagnosis 
Gastric carcinoma is diagnosed on gastroscopy with biopsy, by biopsy of a 
peripheral metastatic lesion or by biopsy or resection of a suspicious intra-
abdominal lesion at the time of laparotomy. 
1.5.3 Surgical resection 
Surgical resection offers the possibility of a cure for gastric carcinoma. For 
tumours limited to the antrum and-/-or pylorus, a partial gastrectomy is the 
preferred surgical procedure. This may be of Billroth I (pyloric resection with 
anastomosis of gastric body to duodenum) or Billroth II (gastric antrectomy with 
gastrojejunostomy) type. Total gastrectomy is performed for proximal tumours, 
while oesophagogastrectomy is performed for tumours arising at the gastro-






1.6.1 Macroscopic pathology 
On gross pathology, gastric carcinomas may be nodular, fungating, ulcerating or 
polypoid. A distinct infiltrative subtype (linitis plastica) results in widespread 
fibrotic thickening of the gastric wall, resembling a thickened leather bottle.  
Ulcerated carcinomas occur most frequently within the pyloric antrum and lesser 
curve. These ulcers have ragged, raised and rolled edges.  
Polypoid, nodular and fungating tumours consist of friable masses, projecting 
into the gastric lumen. These tumours tend to occur along the greater curve and 
fundus. 
 
1.6.2 Microscopic pathology 
The vast majority of tumours are adenocarcinomas, composed of either nests, 
tubules, trabeculae, papillae or discohesive epithelial cells with intracytoplasmic 
mucin vacuoles. Cellular pleomorphism is variable, depending on the subtype 
and degree of differentiation. For all types of advanced adenocarcinoma 
(excluding early gastric carcinoma), there is invasion into and beyond the 
submucosa. Invasive malignant cells may extend to the muscularis propria, serosa 
or into adjacent organs.  
 
1.6.3 Classification systems 
Numerous gastric carcinoma classification systems exist. These include: The 
World Health Organisation (WHO) system [72], Lauren classification [73], Ming 
classification [74], Mulligan and Rember classification [75], Goseki classification 
[76] and Carnerio classification. [77] 
 
The WHO and Lauren classification systems are the most widely used. 
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1.6.3.1 The WHO classification system 
The typing of gastric adenocarcinoma is based on the predominant 
histomorphology of the tumour. [72] The subtypes include: 
- Papillary adenocarcinoma 
- Tubular adenocarcinoma 
- Mucinous adenocarcinoma 
- Signet-ring adenocarcinoma 
Papillary adenocarcinomas are composed of finger-like outgrowths of neoplastic 
glandular epithelium with variable pleomorphism, overlying fibrovascular cores. 
Tubular adenocarcinomas consist of branching glands with tubular architecture, 
lined by atypical neoplastic glandular epithelium and embedded within a fibrous 
stroma. 
Mucinous adenocarcinomas are adenocarcinomas with abundant pools of 
extracellular mucin, comprising more than 50% of the tumour. Well 
differentiated tumours form small glands lined by columnar epithelium. Poorly 
differentiated tumours show linear cords and discohesive epithelial cells with 
intracytoplasmic vacuoles, present within pools of mucin. 
Signet-ring adenocarcinomas are composed of discohesive epithelial cells with a 
large intracytoplasmic mucin vacuole, causing eccentric displacement of the 
nucleus. Additionally, atypical cells with granular eosinophilic cytoplasm and 
neutral mucin, as well as epithelial cells with absent intracytoplasmic mucin, are 




1.6.3.2 The Lauren classification system 
Two subtypes of gastric adenocarcinoma [73] are present: 
- Intestinal-type 
- Diffuse-type 
The intestinal-type is composed of large pleomorphic, mitotically active 
epithelial cells with large nuclei, prominent nucleoli and variable amounts of 
intracytoplasmic mucin. The tumour cells form glands, nests, sheets, tubules and 
may demonstrate papillary architecture. 
 
The diffuse-type is predominantly composed of poorly cohesive or discohesive 
epithelial cells with mild nuclear hyperchromasia and minimal pale eosinophilic-
to-clear cytoplasm, often infiltrating into a desmoplastic stroma. Signet-ring 
morphology is often apparent. Gland formation is inconspicuous, but may be 




1.6.4 Gastric carcinoma staging 
Gastric carcinomas are staged according to the 2009 7th edition TNM tumour 
staging system [78], which characterises the extent of the lesion according to the 
parameters of size of the primary tumour (T), regional lymph node involvement 
(N) and distant metastatic spread (M). 
T – primary tumour 
pT1 – Tumour invades lamina propria or submucosa 
pT2 – Tumour invades muscularis propria or subserosa 
  pT2a  - tumour invades muscularis propria 
 pT2b - tumour invades subserosa 
pT3 – tumour penetrates the serosa (visceral peritoneum) without invasion of 
adjacent structures. 
PT4 – tumour invades adjacent structures 
 
N – regional lymph nodes 
pN0 – No regional lymph node metastasis 
pN1 – Metastasis in 1-6 regional lymph nodes 
pN2 - Metastasis in 7-15 regional lymph nodes 
pN3 - Metastasis in more than 15 regional lymph nodes 
 
M – Distant metastasis 
M0 – No distant metastasis 




1.7 Early gastric carcinoma 
Early gastric carcinoma is defined as a carcinoma limited to the mucosa (mucosal 
subtype); or the mucosa and submucosa only (submucosal subtype), irrespective 
of the presence of lymph node metastases. When compared to advanced gastric 
carcinomas, these tumours have a much better prognosis, with up to 90% 5 year 
survival. [91] 
1.7.1 Macroscopic pathology and classification 
Early gastric carcinoma is classified according to the Japanese 
Gastroenterological Endoscopic Society guidelines, which are based on the 
macroscopic endoscopic appearance of the tumour. (Table 3).   
Table 3. Macroscopic classification of early gastric carcinoma 
Type I Protruded type 
- A polypoid, nodular or villous 
tumour that projects into the lumen 
Type II Superficial type 
- Type IIa   Elevated subtype 
- A well circumscribed plaque-like 
lesion that is slightly elevated 
above the mucosal surface 
- Type IIb   Flat subtype 
- No macroscopic abnormality 
visible 
- Type IIc   Depressed subtype 
- The surface of the lesion is slightly 
depressed below the adjacent 
mucosa 
Type III Excavated type 







The occurrence of gastric carcinoma in South Africa and in particular within the 
Western Cape Province has not been well documented. This study took into 
account the current worldwide knowledge base regarding the specific 
demographics, morphology and immunohistochemical staining profile of gastric 
adenocarcinoma and compared these features to cases found within the Western 
Cape. 
 
2.1  Study aims 
The aims of this study are as follows: 
- To interrogate the WNT signaling pathway using selected protein expression by 
immunohistochemistry and correlating these with tumour subtypes. 
 - To assess Her2/neu expression and correlate this with morphologic subtypes 
 
2.2 Study objectives 
To determine aberrations in the expression of β-catenin, E-cadherin (extracellular 
and cytoplasmic domains) and DVL1 in gastric carcinoma subtypes. 
Additionally, to determine Her2/neu overexpression by immunohistochemistry 






2.3 Ethics approval 
Ethics approval was obtained from the University of Cape Town (UCT) Faculty 
of Health Sciences Human Research Ethics Committee (Reference number 
504/2009) as part of the broader study proposal titled “Molecular analysis and 
identification of biomarkers from formalin fixed paraffin embedded gastric 
cancers”. The research proposal for this MMed project obtained scientific 
approval from both the Department of Clinical Laboratory Sciences Research 
Committee and the Faculty of Health Sciences Research Committee at UCT. 
Funding for this study was obtained from the Cancer Association of South Africa 
(CANSA), National Health Laboratory Service (NHLS) and National Research 
Fund (NRF). 
 
2.4 Materials and methods 
2.4.1 Acquisition of cases 
A retrospective study was undertaken. A computerised DISA search of the 
database of the Division of Anatomical Pathology, University of Cape Town / 
National Health Laboratory Service was performed, searching for all cases of 
gastric carcinoma resections between January 2003 and December 2011. 
97 gastric adenocarcinoma resection cases were identified. Cases were allocated 
study numbers and patients’ names and other identification details were 
anonymised. Archived stained slides of the cases were retrieved and reviewed. 
The diagnosis in each case was confirmed and the morphological data recorded. 
Archival tissue blocks were retrieved and additional sections cut for 
immunohistochemistry. 
The pathology reports of the cases studied were consulted to document the 
patient’s age and gender; type of procedure; size and mass of the gross specimen; 





The following primary antibodies were used (Table 4): β-catenin, DVL1, E-
cadherin extracellular domain (36B5), E-cadherin cytoplasmic domain (36/E-
cadherin) and Her2/neu. 
 
Table 4: Primary antibodies 
Primary 
antibody 






































Dako EDTA 1:200 45 Breast 
carcinoma 
 
A negative control, in which the primary antibody was replaced by PBS (buffer), 





A representative formalin fixed paraffin embedded tissue block was retrieved for 
each case from the archive, after reviewing the initial haematoxylin and eosin 
(H&E) stained slides.  
- Paraffin wax embedded sections were cut onto 3-
aminopropyltriethoxysilane (APES) coated slides and heat-fixed 
overnight at 37°C to adhere sections to slides. 
- Sections were dewaxed through xylene, rehydrated in graded ethanol and 
washed in water. 
- Endogenous peroxidase activity was blocked by treating slides with a 1% 
hydrogen peroxide (H2O2) in water solution for 15 minutes. 
- Slides were washed well in water. 
- Antigen retrieval was performed by pressure-cooking slides in either 
citrate buffer at pH 6 for 2 minutes or EDTA (pH8) for 1 minute at full 
pressure. 
- Slides were then immediately immersed in water. 
- Slides were rinsed with phosphate buffered saline solution (PBS pH 7.6). 
- Non-specific binding was blocked by treating slides with a 5% Goat 
Serum Solution (DAKO #X0907) at a concentration of 1:20 
- Serum was then be drained off. 
- Sections were incubated with primary antibody at room temperature at 
specified times and dilutions. 
- Sections were washed well with PBS Buffer. 
- Sections were incubated with DAKO Envision labelled Polymer, HRP 
(DAKO #K4001) for 30 minutes at room temperature. 
- Sections were washed well with PBS buffer. 
- Positivity was developed by applying the chromogenic substrate 3.3 –
diaminobenzidine (DAKO K3466) for 5-10 minutes. 
- Slides were washed in running tap water. 
- Slides were immersed in a 1% copper sulphate (CuSO4) solution for 5 
minutes. 
- Slides were washed in running tap water. 
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- Slides were counterstained in haematoxylin, blued in Scott’s tap water. 
- Slides were then washed in water, dehydrated using graded alcohols, 
cleared with xylene and mounted with rapid mountant medium (Entellan). 
 
2.4.4  Interpretation of staining 
β-catenin immunohistochemical staining was scored according to the protocol 
devised by Jass et al [92]. 
One point was allocated for loss of cell membrane staining; 1 for slight increase 
in cytoplasmic staining, 2 for marked increase in cytoplasmic staining; 1 for 
slight nuclear staining and 2 for pronounced nuclear staining. This tallies up to a 
maximum score of 5. According to this protocol, cases scoring 4 or more were 
regarded as positive for abnormal β-catenin immunolocalisation. 
 
Dishevelled (DVL1), E-cadherin extracellular domain (36B5) and E-cadherin 
cytoplasmic domain (36/E-cadherin) immunohistochemical staining was scored 
according to the protocol used by Chetty et al. [93].  
This scoring system regards only moderate and/or strong immunostaining as 
significant. The degree of positivity is quantified as follows:  
- a score of 0 if less than or equal to 5% of tumour cells stained 
- a score of 1 if 6% to 50% of tumour cells stained 
- a score of 2 if more than 50% of tumour cells stained 
Additionally, the cellular location of the immunoreactivity was noted. 
 
For E-cadherin (extracellular domain) immunohistochemical stains, membranous 
or a combination of membranous and cytoplasmic staining represented normal E-
cadherin localisation. Any deviation from this staining pattern (including absent 
staining) was considered immunohistochemically abnormal cellular localisation 
of the extracellular domain of E-cadherin. 
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For E-cadherin (cytoplasmic domain) immunohistochemical stains, cytoplasmic 
or a combination of membranous and cytoplasmic staining represented normal E-
cadherin localisation. Any deviation from this staining pattern (including absent 
staining) was considered immunohistochemically abnormal cellular localisation 
of the cytoplasmic domain of E-cadherin 
Her2/neu immunohistochemical staining was scored according to the criteria used 
in the ToGA trial [84].  This scoring system is summarised in Table 5. 
 
Table 5: Criteria used in the ToGA trial for scoring Her2/neu expression by 
immunohistochemistry 
Her2/neu score Immunohistochemical 




0 No reactivity or 
membranous reactivity in 




1+ Faint/barely perceptible 
membranous reactivity in ≥ 
10% of tumour cells; cells 





2+ Weak to moderate 
complete, basolateral or 
lateral membranous 





3+ Strong complete, 
basolateral or lateral 
membranous reactivity in  







2.4.5 Tumour morphology 
Gastric adenocarcinomas were defined as a primary malignant epithelial 
neoplasm demonstrating glandular differentiation, either through the formation of 
neoplastic glands or by the presence of discrete intracellular mucin. 
The intestinal-type tumours were characterised by mitotically active epithelial 
cells with large nuclei, prominent nucleoli and intracytoplasmic mucin. The 
tumour cells formed glands, nests, sheets and tubules. 
The diffuse-type tumours were characterised by linear cords of poorly cohesive 
or discohesive epithelial cells with moderate to severe nuclear hyperchromasia 
and minimal pale eosinophilic-to-clear cytoplasm. Signet-ring morphology was 
often apparent. Gland formation was inconspicuous. Occasional tumours showed 
small glands within the superficial regions of the neoplasm. 
Mixed type tumours showed features of both intestinal and diffuse type tumour 
morphology. 
 
2.4.6 Grading of tumours 
Tumours were classified into well differentiated, moderately differentiated, 
poorly differentiated and undifferentiated carcinomas, based on the 2009 7th 
edition TNM tumour staging system [78]. 
According to this system, gastric carcinomas are graded based on the extent of 








Table 6: Tumour grading 
Grade 1 Well differentiated 
adenocarcinoma 
Greater than 95% of the tumour is 
composed of glands 
Grade 2 Moderately differentiated 
adenocarcinoma 
50 – 95% of the tumour is composed 
of glands 
Grade 3 Poorly differentiated 
adenocarcinoma 
49% or less of the tumour is 
composed of glands 
Grade 4 Undifferentiated 
carcinoma 
High grade carcinoma that cannot be 
further classified as 
adenocarcinoma, squamous cell 





2.4.7 Site of tumour 
Tumour site was described as either proximal (involving cardia, fundus or body) 
or distal (involving antrum or pylorus). Information regarding the tumour site 





2.4.8  Interpretation of lymph node metastasis 
The 2009 7th edition TNM tumour staging system [78] was used for evaluating 
lymph node metastases. Regional lymph nodes were described as positive for 
metastatic tumour if clusters of gastric adenocarcinoma cells, measuring more 
than 0.2mm in diameter, were present within the lymph node.  
If no tumour cells, single tumour cells or isolated clusters of tumour cells 
measuring less than 0.2mm were noted within the lymph node, these were 
considered negative for nodal metastatic carcinoma.  
Discontinuous tumour deposits located within the subserosal tissue adjacent to 
the gastric adenocarcinoma, where no evidence of a residual lymph node existed, 
were considered positive for nodal metastatic carcinoma. 
 
2.5 Statistical analysis 
The Fisher’s exact test, Shapiro-Wilk test, Bonferroni test, Chi squared test and 
Kappa test were used in the analysis of variables. Computerised statistical 
analysis and interpretation was performed using Stata 12.0 statistical software 
(StataCorp LP, College Station, USA).  
Results were considered statistically significant if P < 0.05 





All cases were confirmed as gastric adenocarcinomas. There were 97 cases of 
gastric adenocarcinomas, comprising 39 intestinal type and 51 diffuse type 
gastric adenocarcinomas. 7 tumours showed mixed intestinal and diffuse 
morphology [Figure 2; Appendix 1].  
 
a. Intestinal-type adenocarcinoma  
(H&E, 10x obj mag) 
 
b. Diffuse-type adenocarcinoma 
(H&E, 10x obj mag) 
 
c. Intestinal-type adenocarcinoma  
      (H&E, 40x obj mag) 
 
d. Diffuse-type adenocarcinoma 
(H&E, 40x obj mag) 
 
Figure 2: Photomicrographs of gastric adenocarcinoma. (a) Neoplastic cells 
forming nests and tubules. (b) Poorly cohesive cords of tumour cells present 
within a desmoplastic stroma. (c) Large tumour cells with eosinophilic 
cytoplasm, vesicular nuclei and prominent nucleoli. (d) Tumour cells with an 




Age was not provided on the request form or within the available clinical details 
in two cases (cases 34 and 42). These two cases were omitted from the analysis 
of age, thus resulting in 95 cases being statistically evaluated 
The age range for all cases combined was 18 – 84 years, with a mean age of 57.1 
years. Within the intestinal type adenocarcinomas, the age range varied from 32 – 
84 years, with a mean age of 63.1 years. Diffuse type adenocarcinomas 
demonstrated an age range from 33 – 82 years, with a mean age of 54.5 years. 
Gastric adenocarcinomas showing mixed morphology had an age range from 18 – 
57 years, with a mean age of 45 years [Table 7]. 
 
Table 7: Comparison of age (years) between gastric adenocarcinoma groups 
 All cases Intestinal type Diffuse type Mixed type 
Number of 
cases 
95 37 51 7 
Age range 
(years) 
18 - 84 32 - 84 33 - 82 18 – 57 
Mean age +/- 
SD (years) 
57.1 
 +/- 13.7 
63.1  
+/- 12.9 
54.5   
+/- 12.5 
45 
+/-  12.9 
 
Statistically significant differences were noted when comparing age amongst 
intestinal and diffuse gastric adenocarcinoma subtypes (P = 0.007) and between 








Table 8: Comparison of age by tumour type (Bonferroni test).  
 Intestinal type Diffuse type 
Diffuse type -8.61791 
P = 0.007 
 
Mixed type -18.1081 
P = 0.002 
-9.4902 
P = 0.200 
 
3.2 Gender 
Gender information was provided on the request forms of all 97 cases. [Table 9] 
Table 9: Comparison of gender between gastric adenocarcinoma groups 
 All cases Intestinal type Diffuse type Mixed type 
Number of 
cases 
97 39 51 7 
Male (%) 51 (53%) 24 (62%) 22 (43%) 3 (43%) 
Female (%) 48 (47%) 15 (38%) 29 (57%) 4 (57%) 
Fisher’s exact test P = 0.271 
 
When comparing all cases of gastric carcinomas, more males than females were 
afflicted. Intestinal type gastric adenocarcinomas were noted in more males 
(62%) than females (38%), while diffuse type and mixed type tumours showed a 
female predominance (57% each). However, no statistically significant 
differences were present in the comparison of the tumour subtypes by gender. 
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3.3 Tumour differentiation 
Sixty seven percent (67%) of intestinal type tumours were well or moderately 
differentiated while 100% of diffuse type carcinomas were poorly differentiated. 
All cases of tumours with mixed intestinal and diffuse morphology (mixed 
subtype), were poorly differentiated. A significantly higher proportion of diffuse 
type tumours were poorly differentiated (P < 0.0001) when compared to intestinal 
type tumours. A significantly greater proportion of mixed type tumours showed 
poor differentiation when compared to intestinal type tumours [Tables 10 - 13]. 
 Table 10: Comparison of tumour differentiation between gastric adenocarcinoma 
groups 
 All cases Intestinal 
type 
Diffuse type Mixed type 
Well 
differentiated 
2 (1%) 2 (5%) 0 (0%) 0 (0%) 
Moderately 
differentiated 
26 (27%) 26 (67%) 0 (0%) 0 (0%) 
Poorly 
differentiated 
69 (72%) 11 (28%) 51 (100%) 7 (100%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
 
Table 11: Comparison of tumour differentiation between intestinal and diffuse 
type tumours 
 Intestinal type Diffuse type 
Well or moderately 
differentiated 
28 cases 0 cases 
Poorly differentiated  
 
11 cases 51 cases 





Table 12: Comparison of tumour differentiation between intestinal and mixed 
type tumours 
 Intestinal type Mixed type 
Well or moderately 
differentiated 
28 cases 0 cases 
Poorly differentiated  11 cases 7 cases 
Chi-squared test P =  0.0004 
 
Table 13: Comparison of tumour differentiation between diffuse and mixed type 
tumours 
 Diffuse type Mixed type 
Well or moderately 
differentiated 
0 cases 0 cases 
Poorly differentiated  51 cases 7 cases 









3.4 Depth of invasion 
The majority of intestinal type carcinomas showed invasion into the muscularis 
propria or subserosa (pT2). This contrasted with more extensive serosal (pT3) 
tumour invasion noted in diffuse type adenocarcinomas. Mixed type tumours 
showed an equal proportion of pT2 and pT3 invasion [Table 14].  
No statistically significant differences were present in comparison of the 
minimal–to-moderately invasive (pT1/pT2) tumours to deeply invasive 
(pT3/pT4) tumours amongst the tumour subtypes [Tables 15-17]. 
 
Table 14: Comparison of tumour depth of invasion between gastric 
adenocarcinoma groups 
 All cases Intestinal type Diffuse type Mixed type 
pT1 12 (12%) 4 (10%) 8 (16%) 0 (0%) 
pT2 42 (44%) 20 (51%) 19 (37%) 3 (43%) 
pT3 40 (41%) 15 (39%) 22 (43%) 3 (43%) 
pT4 3 (3%) 0 (0%) 2 (4%) 1 (14%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
 
Table 15: Comparison of tumour depth of invasion between intestinal and diffuse 
type tumours: 
 Intestinal type Diffuse type 
pT1 or pT2 24 cases 27 cases 
pT3 or pT4 15 cases 24 cases 






Table 16: Comparison of tumour depth of invasion between intestinal and mixed 
type tumours: 
 Intestinal type Mixed type 
pT1 or pT2 24 cases 3 cases 
pT3 or pT4 15 cases 4 cases 
Chi squared test P =  0.3553 
 
Table 17: Comparison of tumour depth of invasion between diffuse and mixed 
type tumours: 
 Diffuse type Mixed type 
pT1 or pT2 27 cases 3 cases 
pT3 or pT4 24 cases 4 cases  







3.5 Site of tumour 
Most tumours had a proximal distribution (57%), with all tumour groups showing 
a proximal predominance. No statistically significant differences between tumour 
location and tumour subtypes were present. [Table 18] 
 
Table 18: Comparison of tumour site between gastric adenocarcinoma groups 
 Intestinal 
type 









18 (46%) 22 (43%) 2 (29%) 42 
Fisher’s exact test 






3.6 Nodal metastases 
Lymph nodes were recovered in 94 of the 97 gastrectomy specimens. All 
tumour subtypes showed regional lymph node metastases, detected in 62% 
of intestinal type, 61% of diffuse type and 85% of mixed tumours 
respectively. In the 94 cases where lymph nodes were recovered, no 
statistically significant differences in regional lymph node metastases were 
present amongst the tumour subtypes. [Tables 19-22] 
 
Table 19: Comparison of regional lymph node metastases between gastric 
adenocarcinoma groups. 
 All cases Intestinal 
type 








33 (34%) 13 (33%) 19 (37%) 1 (15%) 
No lymph 
nodes present 
3 (3%) 2 (5%) 1 (2%) 0 (0%) 
 
Table 20: Comparison of regional lymph node metastases between 
intestinal and diffuse type tumours 
 Intestinal type Diffuse type 
Positive for nodal 
metastasis 
24 (62%) 31 (61%) 
Negative for 
nodal metastasis 
13 (33%) 19 (37%) 







Table 21: Comparison of regional lymph node metastases between 
intestinal and mixed type tumours 
 Intestinal type Mixed type 
Positive for nodal 
metastasis 
24 (62%) 6 (85%) 
Negative for 
nodal metastasis 
13 (33%) 1 (15%) 
Chi squared test P = 0.2771 
 
Table 22: Comparison of regional lymph node metastases between diffuse     
and mixed type tumours 
 Diffuse type Mixed type 
Positive for nodal 
metastasis 
31 (61%) 6 (85%) 
Negative for 
nodal metastasis 
19 (37%) 1 (15%) 






Her2/neu immunohistochemical staining was performed on all 97 cases       
[Figure 3]. 
 
a. External control (Her2/neu, 20x obj 
mag) 
 
b. Intestinal type gastric 
adenocarcinoma score = 3+ 
(Her2/neu, 20x obj mag) 
 
c. Diffuse gastric adenocarcinoma 
score = 1+ (Her2/neu, 20x obj mag) 
 
d. Intestinal type gastric 
adenocarcinoma granular staining 
(Her2/neu, 20x obj mag) 
 
Figure 3. (a) Her2/neu breast carcinoma positive external control showing 
complete strong membrane staining. (b) Gastric adenocarcinoma (intestinal type) 
Her2/neu showing complete strong membranous staining in 100% of tumour 
cells. (c) Diffuse gastric adenocarcinoma Her2/neu showing faint barely 
perceptible membranous staining. (d) Non-specific granular cytoplasmic staining 
in intestinal type gastric adenocarcinoma epithelial cells. 
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Twelve (12) of the 97 cases demonstrated 3+ immunopositivity and thus were 
considered to overexpress Her2/neu. A statistically significant proportion (P = 
0.0174) of intestinal type tumours (23%) showed Her2/neu overexpression when 
compared to diffuse type tumours (6%). [Table 25] 
A single case showed non-specific granular cytoplasmic Her2/neu staining. This 
staining did not represent overexpression. 




All cases Intestinal type Diffuse type Mixed type 
0 15 (15%) 4 (10%) 9 (18%) 2 (29%) 
1+ 57 (60%) 20 (51%) 33 (64%) 4 (57%) 
2+ 12 (12%) 5 (13%) 6 (12%) 1 (14%) 
3+ 12 (12%) 9 (23%) 3 (6%) 0 (0%) 
Granular 
cytoplasmic 
1 (%) 1 (3%) 0 (0%) 0 (0%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
 
Table 24: Comparison of Her2/neu immunolocalisation between gastric 
adenocarcinoma groups. 
 All cases Intestinal 
type 








85 (88%) 30 (77%) 48 (94%) 7 (100%) 




Table 25: Comparison of Her2/neu immunolocalisation between intestinal and 
diffuse gastric adenocarcinoma groups. 








30 cases 48 cases 
Chi squared test P = 0.0174 
 
 
Table 26: Comparison of Her2/neu immunolocalisation between intestinal and 
mixed gastric adenocarcinoma groups. 








30 cases 7 cases 








Table 27: Comparison of Her2/neu immunolocalisation between diffuse and 
mixed gastric adenocarcinoma groups. 








48 cases 7 cases 








Immunohistochemical staining for β-catenin was performed on all 97 cases of 









b. β-catenin score = 4 (intestinal type 





c. β-catenin score = 3 (diffuse type 





d. β-catenin score = 5 (diffuse type 
gastric adenocarcinoma), 40x obj 
mag 
Figure 4. (a) β-catenin positive external control showing membrane staining in 
normal breast ducts. (b) Moderate cytoplasmic and strong nuclear β-catenin 
staining with loss of membrane staining, equating to a score of 4 in an intestinal-
type gastric adenocarcinoma. (c) Strong nuclear β-catenin staining with loss of 
membrane staining, equating to a score of 3 in a diffuse type gastric 
adenocarcinoma. (d) Strong nuclear and cytoplasmic β-catenin staining with loss 




Fourteen (14) of the 97 gastric adenocarcinoma cases (14%) showed abnormal 
localisation of β-catenin as detected by immunohistochemistry. Abnormal β-
catenin immunolocalisation was noted in all three gastric adenocarcinoma 
subgroups, occurring in 13%, 16% and 14% of intestinal type, diffuse type and 
mixed type tumours, respectively [Table 28]. 
 
No statistically significant difference in β-catenin immunolocalisation amongst 
the tumour subgroups was evident [Tables 29-31]. 
 
Table 28: Comparison of abnormal β-catenin immunolocalisation between gastric 
adenocarcinoma groups. 
 
 All cases Intestinal 
type 
Diffuse type Mixed type 
Abnormal 
localisation 




83 (86%) 34 (87%) 43 (84%) 6 (86%) 
 
 
Table 29: Comparison of abnormal β-catenin immunolocalisation between 
intestinal and diffuse type tumours 
 Intestinal type Diffuse type 
Abnormal localisation 5 cases 8 cases 
No abnormality 
detected 
34 cases 43 cases 






Table 30: Comparison of abnormal β-catenin immunolocalisation between      
intestinal and mixed type tumours 
 Intestinal type Mixed type 
Abnormal localisation 5 cases 1 case 
No abnormality 
detected 
34 cases 6 cases 
Chi squared test P =  0.9156 
 
Table 31: Comparison of abnormal β-catenin immunolocalisation between      
diffuse and mixed type tumours 
 Diffuse type Mixed type 
Abnormal localisation 8 cases 1 case 
No abnormality 
detected 
43 cases 6 cases 






3.9 Her2/neu and β-Catenin 
No significant correlations were noted in the comparison of aberrant β-catenin 
immunohistochemical localisation and Her2/neu overexpression amongst the 
different groups of adenocarcinomas. Only a single case showed a combination 
of Her2/neu overexpression and aberrant β-catenin immunohistochemical 
localisation [Tables 32-35]. 
 
Table 32: Correlation between Her2/neu and β-Catenin staining in all gastric 
adenocarcinomas. 




11 cases 72 cases 
Abnormal β-Catenin 
localisation 
1 case 13 cases 
Chi squared test P = 0.5206 
 
Table 33: Correlation between Her2/neu and β-Catenin staining in intestinal type 
gastric adenocarcinomas. 




9 cases 25 cases 
Abnormal β-Catenin 
localisation 
0 case 5 cases 
Chi squared test P =  0.1896 
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Table 34: Correlation between Her2/neu and β-Catenin staining in diffuse type 
gastric adenocarcinomas. 




2 cases 41 cases 
Abnormal β-Catenin 
localisation 
1 case 7 cases 
Chi squared test P =  0.3863 
 
Table 35: Correlation between Her2/neu and β-Catenin staining in mixed type 
gastric adenocarcinomas. 




0 cases 6 cases 
Abnormal β-Catenin 
localisation 
0 case 1 cases 









3.10 E-cadherin (extracellular domain) 
All 97 cases were immunohistochemically stained to detect the extracellular 
domain of E-cadherin [Figure 5]. 
 
a. Positive external control 
(E-cadherin extracellular 
domain,  20x obj mag) 
 
b. Negative external control 
(E-cadherin extracellular domain, 20x 
obj mag) 
 
c. E-cadherin extracellular domain,  
40x obj mag) 
 
d. E-cadherin extracellular domain,  
40x obj mag) 
Figure 5. (a) E-cadherin (extracellular domain) positive external control showing 
strong membranous staining in prostatic gland epithelium. (b) E-cadherin 
(extracellular domain) negative external control showing no staining of prostatic 
gland epithelium. (c) E-cadherin (extracellular domain) showing strong 
membrane staining in a diffuse type tumour. (d) E-cadherin (extracellular 




Seven cases (18%) of intestinal type tumours showed abnormal cytoplasmic 
localisation of E-cadherin, while being seen in 29 cases (57%) of diffuse type 
tumours. Abnormal E-cadherin localisation was manifested by absent staining in 
4 cases (8%) and cytoplasmic staining in 25 cases (49%). All mixed type tumours 
showed normal E-cadherin localisation [Table 36]. 
Comparing intestinal and diffuse type tumour subgroups, a significantly greater 
proportion of diffuse type tumours (P < 0.001) showed abnormal E-cadherin 
immunolocalisation [Table 37]. A significantly greater proportion (P = 0.0047) of 
diffuse type tumours showed abnormal E-cadherin immunolocalisation when 
compared to mixed type tumours [Table 39]. 
Table 36: Comparison of E-cadherin (extracellular domain) immunolocalisation 
between gastric adenocarcinoma groups. 
 All cases  Intestinal type Diffuse type Mixed type 
Normal 
localisation 
61 (63%) 32 (82%) 22 (43%) 7 (100%) 
Abnormal 
localisation 
36 (37%) 7 (18%) 29 (57%) 0 (0%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
 
 
Table 37: Comparison of immunolocalisation of E-cadherin (extracellular 
domain) in intestinal and diffuse type tumours. 
 Intestinal type Diffuse type 
Normal 
immunolocalisation 
32 cases 22 cases 
Abnormal 
immunolocalisation 
7 cases 29 cases 




Table 38: Comparison of immunolocalisation of E-cadherin (extracellular 
domain) in intestinal and mixed type tumours. 
 Intestinal type Mixed type 
Normal 
immunolocalisation 
32 cases 7 cases 
Abnormal 
immunolocalisation 
7 cases 0 cases 
Chi squared test P = 0.2234 
 
 
Table 39: Comparison of immunolocalisation of E-cadherin (extracellular 
domain) in diffuse and mixed type tumours. 
 Diffuse type Mixed type 
Normal 
immunolocalisation 
22 cases 7 cases 
Abnormal 
immunolocalisation 
29 cases 0 cases 










Table 40: Distribution of E-cadherin (extracellular domain) staining between 
gastric adenocarcinoma groups. 
E-cadherin 
staining 
All cases  Intestinal type Diffuse type Mixed type 
No staining 4 (4%) 0 (0%) 4 (8%) 0 (0%) 
Membranous 37 (38%) 22 (56%) 8 (16%) 7 (100%) 
Membranous & 
cytoplasmic 
24 (25%) 10 (26%) 14 (27%) 0 (0%) 
Cytoplasmic 32 (33%) 7 (18 %) 25 (49%) 0 (0%) 
Nuclear & 
cytoplasmic 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Nuclear 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Nuclear & 
Membranous 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
 
Comparing the proportion of tumour cells showing immunopositive staining 
between intestinal and diffuse tumours, a significantly greater proportion of 
diffuse type tumours (P = 0.0011) showed staining in ≤ 5% of tumour cells 
compared to intestinal type tumours [Table 42]. 
 
Table 41: Comparison of proportion of E-cadherin (extracellular domain) staining 




All cases  Intestinal type Diffuse type Mixed type 
0 (≤5%) 12 (12%) 0 (0%) 12 (24%) 0 (0%) 
1 (6 – 50%) 3 (3%) 1 (3%) 2 (4%) 0 (0%) 
2 (>50%) 82 (85%) 38 (97%) 37 (73%) 7 (100%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
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Table 42: Comparison of proportion of E-cadherin (extracellular domain) staining 
between intestinal and diffuse tumours 
 Intestinal type Diffuse type 
≤5% tumour cells 
staining 
0 cases 12 cases 
> 5% tumour cells 
staining 
39 cases 39 cases 
Chi squared test P = 0.0011 
 
Table 43: Comparison of proportion of E-cadherin (extracellular domain) staining 
between intestinal and mixed tumours 
 Intestinal type Mixed type 
≤5% tumour cells 
staining 
0 cases 0 cases 
> 5% tumour cells 
staining 
39 cases 7 cases 
Chi squared test P = 1.000 
 
Table 44: Comparison of proportion of E-cadherin (extracellular domain) staining 
between diffuse and mixed tumours 
 Diffuse type Mixed type 
≤5% tumour cells 
staining 
12 cases 0 cases 
> 5% tumour cells 
staining 
39 cases 7 cases 




3.11 E-cadherin (cytoplasmic domain) 
All 97 cases were immunohistochemically stained to detect the cytoplasmic 
domain of E-cadherin [Figure 6].  
 
a. Positive external control 
(E-cadherin cytoplasmic domain, 
40x obj mag) 
 
b. Negative external control  
(E-cadherin cytoplasmic domain, 
40x obj mag) 
 
c. E-cadherin (cytoplasmic 
domain, 40X obj mag) 
 
d. E-cadherin (cytoplasmic domain, 
40X obj mag) 
 
Figure 6. (a) E-cadherin (cytoplasmic domain) positive external control showing 
membranous and cytoplasmic staining in keratinocytes of normal skin. (b) E-
cadherin (cytoplasmic domain) negative external control showing no staining of 
skin keratinocytes. (c) E-cadherin (cytoplasmic domain) showing strong 
membrane and cytoplasmic staining in an intestinal type gastric adenocarcinoma. 
(d) E-cadherin (cytoplasmic domain) showing strong cytoplasmic staining in a 






Eight cases of the 97 gastric adenocarcinomas (8%) showed abnormal E-cadherin 
localisation, with 6 cases (12%) noted within diffuse type adenocarcinomas and 2 
cases (5%) noted within intestinal type adenocarcinomas. No adenocarcinomas 
with mixed morphology demonstrated abnormal E-cadherin localisation. [Table 
45] 
No statistically significant differences were present in either E-cadherin 
immunolocalisation or proportion of positive tumour cells between the tumour 
subgroups.  
 
Table 45: Comparison of E-cadherin (cytoplasmic domain) immunolocalisation 
between gastric adenocarcinoma groups. 
 All cases  Intestinal type Diffuse type Mixed type 
Normal 
localisation 
89 (92%) 37 (95%) 45 (88%) 7 (100%) 
Abnormal 
localisation 
8 (8%) 2 (5%) 6 (12%) 0 (0%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
 
 
Table 46: Comparison of E-cadherin (cytoplasmic domain) immunolocalisation 
between intestinal and diffuse type tumours. 
 Intestinal type Diffuse type 
Normal localisation 37 cases 45 cases 
Abnormal localisation 2 cases 6 cases 







Table 47: Comparison of E-cadherin (cytoplasmic domain) immunolocalisation 
between intestinal and mixed type tumours. 
 Intestinal type Mixed type 
Normal localisation 37 cases 7 cases 
Abnormal localisation 2 cases 0 cases 
Chi squared test P =  0.5401 
 
Table 48: Comparison of E-cadherin (cytoplasmic domain) immunolocalisation 
between diffuse and mixed type tumours. 
 Diffuse type Mixed type 
Normal localisation 45 cases 7 cases 
Abnormal localisation 6 cases 0 cases 




Table 49: Distribution of E-cadherin (cytoplasmic domain) staining between 
gastric adenocarcinoma groups. 
E-cadherin 
staining 
All cases  Intestinal type Diffuse type Mixed type 
No staining 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Membranous 1 (1%) 1 (3%) 0 (0%) 0 (0%) 
Membranous & 
cytoplasmic 
68 (70%) 27 (68%) 37 (73%) 4 (57%) 
Cytoplasmic 21 (22%) 10 (26%) 8 (16%) 3 (43%) 
Nuclear & 
cytoplasmic 
4 (4%) 1 (3%) 3 (6%) 0 (0%) 
Nuclear 2 (2%) 0 (0%) 2 (4%) 0 (0%) 
Nuclear & 
Membranous 
1 (1%) 0 (0%) 1 (1%) 0 (0%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
 
 
Table 50: Comparison of proportion of E-cadherin (cytoplasmic domain) staining 




All cases Intestinal type Diffuse type Mixed type 
0 (<5%) 1 (1%) 0 (0%) 1 (2%) 0 (0%) 
1 (6 – 50%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
2 (>50%) 96 (99%) 39 (100%) 50 (98%) 7 (100%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 
Fisher’s exact 
test 





3.12 E-cadherin cytoplasmic and extracellular domains 
There was a statistically significant correlation (P = 0.00207) amongst the 
combined group of tumour subtypes regarding abnormal immunolocalisation of 
the E-cadherin cytoplasmic domain and the E-cadherin membranous domain. 
[Table 51] In addition, a statistically significant (P = 0.02313) proportion of 
diffuse type tumours showed abnormal immunolocalisation of both E-cadherin 
clones. [Table 53] Intestinal and mixed type tumours showed no significant 
correlations regarding immunolocalisation of the two E-cadherin domains. 
 
Table 51: Correlation between E-cadherin (cytoplasmic domain) and E-cadherin 
(extracellular domain) staining in all gastric adenocarcinomas. 













29 cases 7 cases 





Table 52: Correlation between E-cadherin (cytoplasmic domain) and E-cadherin 
(extracellular domain) staining in intestinal type gastric adenocarcinomas. 













6 cases  1 case 
Chi squared test P = 0.22527 
 
Table 53: Correlation between E-cadherin (cytoplasmic domain) and E-cadherin 
(extracellular domain) staining in diffuse type gastric adenocarcinomas. 













23 cases 6 cases 





Table 54: Correlation between E-cadherin (cytoplasmic domain) and E-cadherin 
(extracellular domain) staining in mixed type gastric adenocarcinomas. 













0 cases 0 cases 




3.13 E-cadherin (cytoplasmic domain) and β-catenin 
There was a statistically significant (P = 0.0139) correlation between abnormal 
immunolocalisation of E-cadherin (cytoplasmic domain) and abnormal 
immunolocalisation of β-Catenin amongst diffuse type gastric adenocarcinomas. 
[Table 57] Intestinal and mixed type tumours showed no such correlations. 
 
Table 55: Correlation between E-cadherin (cytoplasmic domain) and β-Catenin 
staining in all gastric adenocarcinomas. 






78 cases 5 cases 
Abnormal β-Catenin 
localisation 
11 cases 3 cases 
Chi squared test P = 0.0526 
 
Table 56: Correlation between E-cadherin (cytoplasmic domain) and β-Catenin 
staining in intestinal type gastric adenocarcinomas. 






32 cases 2 cases 
Abnormal β-Catenin 
localisation 
5 cases 0 cases 




Table 57: Correlation between E-cadherin (cytoplasmic domain) and β-Catenin 
staining in diffuse type gastric adenocarcinomas. 






40 cases 3 cases 
Abnormal β-Catenin 
localisation 
5 cases 3 cases 
Chi squared test P = 0.0139 
 
 
Table 58: Correlation between E-cadherin (cytoplasmic domain) and β-Catenin 
staining in mixed type gastric adenocarcinomas. 






6 cases 0 cases 
Abnormal β-Catenin 
localisation 
1 case 0 cases 








3.14 E-cadherin (extracellular domain) and β-catenin 
No significant correlations were noted in the comparison of aberrant 
immunohistochemical localisation of the extracellular domain of E-cadherin and 
β-catenin amongst the different groups of gastric adenocarcinomas. 
 
Table 59: Correlation between E-cadherin (extracellular domain) and β-Catenin 
staining in all gastric adenocarcinomas. 






55 cases 28 cases 
Abnormal β-Catenin 
localisation 
6 cases 8 cases 
Chi squared test P =  0.0935 
 
Table 60: Correlation between E-cadherin (extracellular domain) and β-Catenin 
staining in intestinal type gastric adenocarcinomas. 






29 cases 5 cases 
Abnormal β-Catenin 
localisation 
3 cases 2 cases 





Table 61: Correlation between E-cadherin (extracellular domain) and β-Catenin 
staining in diffuse type gastric adenocarcinomas. 






20 cases 23 cases 
Abnormal β-Catenin 
localisation 
2 cases 6 cases 
Chi squared test P = 0.2593 
 
Table 62: Correlation between E-cadherin (extracellular domain) and β-Catenin 
staining in mixed type gastric adenocarcinomas. 






6 cases 0 cases 
Abnormal β-Catenin 
localisation 
1 case 0 cases 










Immunohistochemical staining for Dishevelled was performed on all 97 cases of 
gastric adenocarcinoma [Figure 7]. 
 
a. Positive external control 
(Dishevelled, 40x obj mag) 
 
b. Negative external control 
(Dishevelled, 20x obj mag) 
 
c. Intestinal type gastric 
adenocarcinoma score = 1 
Dishevelled, 20x obj mag) 
 
d. Intestinal type gastric 
adenocarcinoma score = 2 
Dishevelled, 20x obj mag) 
 
 
Figure 7. (a) Dishevelled positive external control showing strong cytoplasmic 
staining in breast carcinoma. (b) Dishevelled negative external control showing 
absent staining. (c) Moderate cytoplasmic staining in 6-50% of tumour cells. (d) 





All cases demonstrated moderate to intense cytoplasmic staining in more than 5% 
of tumour cells. No statistically significant differences between the tumour 
subgroups were evident [Table 63]. 





All cases  Intestinal type Diffuse type Mixed type 
0 (<5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
1 (6 – 50%) 9 (9%) 4 (11%) 3 (6%) 2 (38%) 
2 (>50%) 88 (91%) 35 (89%) 48 (94%) 5 (72%) 
Total 97 (100%) 39 (40%) 51 (53%) 7 (7%) 





3.16 Tumour analysis by age group (≤ 40 years and > 40 years) 
Eleven cases (11% of the 95 cases analysed by age) of gastric adenocarcinoma 
were identified in patients 40 years and younger, consisting of 9 intestinal type 
tumours (82%), 1 diffuse type tumour (9%) and 1 mixed type tumour (9%) 
[Table 64]. 
No statistically significant difference (P = 0.0545) existed when comparing 
tumour type by age group. 
Table 64: Comparison of tumour type by age group 
 ≤  40 years old > 40 years old 
Intestinal type 9 44 
Non intestinal type 2 40 
Chi squared test P = 0.0545 
 
Of the eleven cases in younger patients, 6 (54%) were in females and 5 (46%) 
were in males. This did not represent a significant finding (P = 06656) [Table 
65]. 
Table 65: Gender comparison by age group 
 ≤  40 years old > 40 years old 
Male 5 cases 44 
Female 6 cases 40 
Chi squared test P = 06656 
 
One tumour (9%) was moderately differentiated and 10 tumours (91%) were 
poorly differentiated [Table 66]. This did not represent a statistically significant 





Table 66: Comparison of tumour differentiation by age group 
 ≤  40 years old > 40 years old 
Poorly differentiated 10 cases 59 cases 
Well or moderately 
differentiated 
1 case 25 cases 
Chi squared test P = 0.1482 
 
The aforementioned eleven cases were comprised of three pT1 tumours (27%), 
two pT2 tumours (18%), five pT3 tumours (45%) and one pT4 (10%). No 
significant difference (P = 0.5106) was present when comparing depth of tumour 
invasion between the ≤ 40 and >40 year age groups [Table 67]. 
Table 67: Comparison of tumour depth amongst age groups: 
 ≤  40 years old > 40 years old 
pT1 & pT2 5 cases 47 cases 
pT3 & pT4 6 cases 37 cases 
Chi squared test P = 0.5106 
 
Six tumours (55%) arose in a proximal location while 5 tumours (45%) were 
distally located. No significant difference (P = 0.9296) was present when 
comparing tumour location between the younger and older groups [Table 68].  
Table 68: Comparison of tumour location amongst age groups: 
 ≤  40 years old > 40 years old 
Proximal tumours 6 cases 47 cases 
Distal tumours 5 cases  37 cases 




Seven of the eleven cases (64%) demonstrated aberrant E-cadherin (extracellular 
domain) immunolocalisation. This was significantly greater (P = 0.025) 
compared to aberrant immunolocalisation in tumours in patients over the age of 
40 years [Table 69]. 
Table 69: Comparison of E-cadherin (extracellular domain) immunolocalisation 
between age groups. 
 ≤ 40 years old > 40 years old 
Aberrant E-cadherin 
immunolocalisation 
7 cases 25 cases 
Normal E-cadherin 
localisation 
4 cases 59 cases 
Chi squared test P = 0.025 
 
No significant differences (P = 0.933) in aberrant E-cadherin (cytoplasmic 
domain), β-catenin (P = 0.732), Her2/neu (P = 0.789) or Dishevelled (P = 1.000) 





The age range for all cases was 18 – 84 years, with a mean age of 57.1 years. 
This is similar to the findings described in a cohort of 34 cases of gastric 
carcinoma in a South African study. [7] These findings confirm that gastric 
adenocarcinoma is a disease of the middle aged and elderly. 
Eleven cases were identified in patients 40 years or younger, suggesting that 
tumours in patients under the age of 40 years are uncommon. However, a higher 
proportion of young gastric adenocarcinoma cases (11%) were noted in our study 
cohort, when compared to the 5-6% described in the literature. [8, 9, 102]  
Although not a statistically significant finding, tumours occurring in patients 40 
years and younger showed a 0.83 : 1 male to female ratio. This finding is similar 




There were more males (53%) than females (47%) in the study cohort, with a 
male to female ratio of 1.1 : 1. This finding differs markedly from the 2:1 male to 
female ratio described in the Surveillance, Epidemiology and End Results 
(SEERs) database [102]. The exact reason for the increased proportion of female 
patients is unclear, though a possible reason is the small number of cases in our 
study.  The study numbers were also probably too small to achieve a statistically 





4.3 Tumour type, location and differentiation 
A predominance of diffuse type adenocarcinomas occurs in epidemiologically 
low risk regions while intestinal type tumours are more common in high risk 
areas. [6]   South Africa is considered a low-to-intermediate risk region for the 
development of gastric carcinoma. [3] Tumours occurring in low risk areas show 
a proximal distribution. [103]. Fifty three percent (53%) of cases within our study 
showed diffuse type morphology and 57% had a proximal distribution. Although 
no statistically significant differences between tumour location and tumour 
subtype were apparent, the above findings confirm that our cohort is 
representative of tumours found within in the general population. 
Corroboratively, 72% of our cases were poorly differentiated, with a significantly 
higher proportion of diffuse type adenocarcinomas being poorly differentiated 
compared to intestinal type adenocarcinomas.  
Ninety percent (90%) of tumours occurring in patients 40 years and younger were 
poorly differentiated, confirming the findings described in a previous Western 
Cape cohort [8] and within the broader literature [9, 105] 
 
4.4 Her2/Neu 
Statistically significant differences in immunohistochemically detected Her2/neu 
overexpression were noted between the tumour subgroups. Twelve percent (12%) 
of the total cases demonstrated overexpression, which included a significantly 
greater proportion (23%) of intestinal-type tumours compared to only 3 of 31 
cases of diffuse-type tumours which showed overexpression. 
These findings correlate well with previous reports in the literature, confirming 
the morphologic-immunophenotypic association of Her2/neu overexpression and 
intestinal-type morphology. [85-87] In addition, the findings are similar to the 




Targeted therapy (Trastuzumab) is currently approved for the treatment of 
advanced gastric adenocarcinoma and metastatic gastric adenocarcinoma, if the 
carcinoma demonstrates unequivocal evidence of Her2/neu overexpression (by 
immunohistochemistry) or amplification (by FISH). Knowledge of the Her2/neu 
status thus plays an integral role in patient management by identifying patients 
who may benefit from molecular targeted therapy. 
 
4.5 E-cadherin  
A significantly higher proportion of diffuse-type tumours showed abnormal E-
cadherin (extracellular domain) immunolocalisation compared to intestinal type 
tumours. This is similar to the reported findings [81, 82, 83, 90, 105] of diffuse-
type tumours showing abnormal immunolocalisation.  
Five percent, twelve percent and zero percent of intestinal, diffuse and mixed 
tumours respectively, showed abnormal E-cadherin (cytoplasmic domain) 
immunolocalisation.  This did not represent a statistically significant difference. 
However, a statistically significant correlation was noted in diffuse type 
carcinomas showing abnormal immunohistochemical E-cadherin localisation for 
both cytoplasmic and extracellular clones. 
When a comparison of tumours occurring in the younger age group (40 years and 
younger) was made, 7 of the 11 cases showed aberrant E-cadherin (extracellular 
domain) immunolocalisation. This was significant when compared to aberrant 
immunolocalisation in tumours in patients over the age of 40 years. This confirms 
the findings described within the broader literature [8, 9, 105], once again 
highlighting that early-onset gastric carcinomas show abnormalities in E-cadherin 
protein expression. 
An interesting point regarding the exact mechanism for the aberrant 
immunohistochemical expression is raised, as aberrant E-cadherin localisation 
may be due to a mutation (germline or somatic) in the CDH1 gene itself or 
epigenetic alterations of CDH1 promoter regions. Further molecular investigation 
of our cohort would provide valuable answers.  
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4.6 WNT pathway 
Although only 3 of the total 97 cases showed immunohistochemically detected 
abnormalities in both E-cadherin (cytoplasmic domain) and β-Catenin, all of 
these 3 cases occurred in diffuse-type tumours. This represented a statistically 
significant correlation between abnormal E-cadherin (cytoplasmic domain) 
immunolocalisation and abnormal β-Catenin immunolocalisation amongst 
diffuse-type tumours.  
These findings support the argument for the integrally linked role of E-cadherin 
and β-catenin within the WNT signalling pathway. When E-cadherin expression 
is downregulated, the loss of E-cadherin immunohistochemical expression results 
in release of β-catenin into the cytoplasm and subsequent translocation to the 
nucleus. [68, 70, 94] 
In contrast, 8 of the 97 cases showed abnormalities in both E-cadherin 
(extracellular domain) and β-Catenin. However, no statistically significant 
correlations between abnormal E-cadherin (extracellular domain) 
immunolocalisation and abnormal β-Catenin immunolocalisation were found in 
the combined group of gastric adenocarcinomas as a whole, or within the 
constituent tumour subtypes (viz. intestinal, diffuse and mixed). 
Fourteen of the 97 (14%) cases showed abnormal immunolocalisation of β-
catenin, with aberrant immunolocalisation noted within all tumour subgroups 
(13%, 16% and 14% of intestinal type, diffuse type and mixed type tumours, 
respectively). No significant differences were evident between the subtypes of 
gastric adenocarcinoma. This proportion is lower than the 27% detected 
immunohistochemically in a cohort of 303 cases by Woo et al [99], who also 
showed that 37% of diffuse type tumours demonstrated altered β-catenin staining.  
While Woo et al, defined altered β-catenin staining as “strong nuclear staining in 
more than 10% of cancer cells or loss of membranous expression, through either 
no immunoreactivity at the membrane or less than 10% of the tumor cells with 
positive membranous staining,” our study used the protocol as defined by Jass et 
al, 2003. [92]  
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The use of a different protocol in the interpretation of staining and our small 
study numbers are felt to contribute both to the statistical insignificance and the 
contrasting results when compared to the literature.  
Whilst the literature shows a strong association between nuclear β-catenin 
accumulation and intestinal-type morphology [101], this was not apparent in our 
cohort of cases.  In contrast, more diffuse type (16%) than intestinal type (13%) 
tumours showed aberrant β-catenin immunolocalisation. The exact reason for this 
discrepancy is not known. The underlying molecular mechanism for nuclear β-
catenin accumulation may have played a role, as mutations in the β-catenin gene 
itself, WNT signalling pathway activation or APC gene mutations could all result 
in nuclear β-catenin accumulation. 
The direct role of Dishevelled in gastric carcinoma pathogenesis is not well 
established. This has proved to be the case within our study cohort as well, with 
all 97 cases demonstrating moderate to intense cytoplasmic staining in more than 
5% of tumour cells. No statistically significant difference in Dishevelled 
immunostaining was evident between the tumour subgroups. Further 





4.7 Study design 
Our study was limited to gastric resection specimens rather than biopsy samples 
in an attempt to overcome the problem of tumour heterogeneity. Differing 
morphology and immunohistochemical expression profiles may be present within 
the same tumour. With only a small biopsy specimen, the tumour present in the 
biopsy may not be representative of the overall tumour morphology. This has an 
impact on tumour typing and grading. Larger resection specimens may highlight 
focal areas of immunohistochemical staining that may not have been detected on 
a limited biopsy sample. 
A challenge in this study was finding adequate sample numbers. Our study cohort 
was limited to cases starting from 2003, as our current laboratory information 
system (DISA) was implemented in January 2003. Obtaining information from 
older databases proved very challenging, precluding cases prior to 2003 from 
being included in the study cohort. 
A limitation of this study was inadequate patient follow-up to allow comparison 
of prognosis and survival rates between the tumour subgroups, and comparison 
with their immunohistochemical profiles.  
Pre-analytical variables such as type of tissue fixation, concentration of tissue 
fixative, duration of tissue fixation and preparation of the gross sample 
represented factors that could not be controlled directly within this study. It is 
known that under-fixation and the use of tissue preservatives other than 
formaldehyde, can impact on antigen retrieval and result in failure of 
immunohistochemical staining. [106] 
A standard staining method was employed for all cases and each primary 
antibody was optimised prior to starting the study. Satisfactory positive and 
negative external controls were used for each antibody. In addition, positive 
internal controls were noted.  
In an attempt to avoid bias, all slides were coded, thus preventing the observer 
from knowing to which tumour subtype the case belonged. An attempt to limit 
intra-observer variability was made, whereby all cases were scored by the same 
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pathologist, using the same microscope in as few sittings as possible. Scoring of 
the cases was checked by the supervising pathologist. 
It is hoped that the use of defined grading systems for each antibody, meticulous 
attention to cellular location of immunohistochemical staining and the use of 
polymer-based immunohistochemical kits, minimised false-positive results within 
our study. 
A strength of our study is the division of tumours into intestinal, diffuse and 
mixed types, so that the effect of age variables and immunohistochemical 




5. Conclusion and recommendations 
Gastric adenocarcinoma is predominantly a disease of the middle aged and 
elderly within the Western Cape, confirming the findings reported in the 
literature. 
While gastric adenocarcinoma is uncommon in patients under the age of 40 years, 
an increased proportion of cases within the Western Cape occur in those 40 years 
and younger compared to other reported populations. 
When gastric adenocarcinomas do occur in patients under the age of 40 years, 
they are invariably poorly differentiated, confirming the reported literature 
findings. In addition, gastric adenocarcinomas in young patients show a 
significantly higher proportion of abnormal E-cadherin immunolocalisation 
versus tumours in older patients. 
Despite gastric carcinoma worldwide occurring in twice as many males as 
females, our cohort of patients showed almost equal gender distribution. 
As reported in the literature, Her2/neu overexpression is significantly more 
frequent in tumours with intestinal-type morphology compared to those with 
diffuse-type morphology. 
Tumours with diffuse-type morphology show aberrations in E-cadherin 
immunolocalisation. When aberrant immunolocalisation does occur, it involves 
either the E-cadherin extracellular domain alone or results from combined defects 
in the cytoplasmic and extracellular domains. 
As reported, E-cadherin and β-catenin are integrally linked within the WNT 
signalling pathway. Aberrations in the normal functioning of E-cadherin result in 
abnormal accumulation and aberrant localisation of β-catenin. Tumours with 









Appendix 1: Summary of cases of gastric adenocarcinoma 
Case number Age (years) Gender Tumour type 
1 78 Male Intestinal 
2 58 Female Diffuse 
3 54 Male Intestinal 
4 18 Female Mixed 
5 53 Male Diffuse 
6 40 Male Diffuse 
7 38 Female Diffuse 
8 77 Female Intestinal 
9 60 Male Intestinal 
10 54 Male Mixed 
11 51 Female Mixed 
12 84 Male Intestinal 
13 74 Female Diffuse 
14 60 Male Intestinal 
15 59 Female Intestinal 
16 59 Male Intestinal 
17 69 Male Intestinal 
18 50 Female Intestinal 
19 44 Male Diffuse 
20 64 Female Intestinal 
21 53 Male Intestinal 
22 43 Female Mixed 
23 78 Male Intestinal 
24 36 Male Diffuse 
25 79 Male Intestinal 
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26 48 Male Diffuse 
27 70 Female Intestinal 
28 43 Female Diffuse 
29 46 Male Mixed 
30 47 Female Diffuse 
31 52 Male Intestinal 
32 49 Male Intestinal 
33 41 Female Intestinal 
34 na Female Intestinal 
35 60 Male Intestinal 
36 70 Female Intestinal 
37 72 Female Intestinal 
38 46 Male Diffuse 
39 54 Female Intestinal 
40 72 Female Intestinal 
41 81 Male Intestinal 
42 na Female Intestinal 
43 82 Male Intestinal 
44 36 Male Diffuse 
45 46 Female Mixed 
46 66 Male Intestinal 
47 43 Male Intestinal 
48 72 Male Intestinal 
49 62 Male Intestinal 
50 64 Male Intestinal 
51 69 Male Intestinal 
52 73 Female Intestinal 
53 52 Male Intestinal 
54 57 Male Mixed 
55 61 Male Diffuse 
56 76 Female Intestinal 
57 73 Female Diffuse 
94 
 
58 57 Male Intestinal 
59 54 Female Diffuse 
60 58 Female Diffuse 
61 53 Female Diffuse 
62 42 Male Intestinal 
63 52 Female Diffuse 
64 36 Female Diffuse 
65 33 Female Diffuse 
66 78 Female Diffuse 
67 60 Male Diffuse 
68 37 Female Diffuse 
69 62 Female Diffuse 
70 36 Male Diffuse 
71 57 Female Diffuse 
72 41 Female Diffuse 
73 62 Female Diffuse 
74 73 Female Diffuse 
75 64 Male Diffuse 
76 69 Female Diffuse 
77 64 Male Diffuse 
78 32 Female Intestinal 
79 60 Female Diffuse 
80 55 Male Diffuse 
81 65 Female Diffuse 
82 44 Female Diffuse 
83 75 Female Diffuse 
84 69 Female Diffuse 
85 55 Male Diffuse 
86 61 Female Diffuse 
87 60 Male Diffuse 
88 67 Male Diffuse 
89 40 Male Diffuse 
95 
 
90 42 Female Diffuse 
91 57 Male Diffuse 
92 44 Male Diffuse 
93 82 Male Diffuse 
94 49 Female Diffuse 
95 56 Male Diffuse 
96 58 Female Diffuse 
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